IMUGENE LIMITED (IMU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IMU - IMUGENE LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.083

17 Apr
2024

0.000

OPEN

$0.08

0.000

HIGH

$0.09

29,883,731

LOW

$0.08

TARGET
$0.10 20.5% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . EOF . GSS . HXL . IDT . IMM . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PBP . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
IMU: 1
Title FY21
Actual		 FY22
Actual		 FY23
Forecast		 FY24
Forecast
EPS (cps) xxx N/A - 0.8 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-0.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx-
Book Value Per Share xxxxxxxxxxxxxxx3.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-29.8 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-23.10 %
Return on Invested Capital xxxxxxxxxxxxxxx-23.04 %
Return on Assets xxxxxxxxxxxxxxx-22.00 %
Return on Equity xxxxxxxxxxxxxxx-23.10 %
Return on Total Capital xxxxxxxxxxxxxxx-31.13 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx153 M
Price To Book Value xxxxxxxxxxxxxxx3.08

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx-
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx2 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx49 M
Research & Development xxxxxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

16/10/2023

1

Speculative Buy

$0.10

20.48%

While recent share price falls leads Bell Potter to halve its target for Imugene to 10c, the Speculative Buy rating is maintained given positives relating to its developmental allogeneic CD19 CAR-T Azer-cel.

However, an in-license transaction for Azer-cel may require up to US$29m/$46m in cash within 12-15 months.

While Imugene holds the option to settle all but the US$8m upfront component in scrip, the broker feels this is the least preferable option particularly at the current market price.

Just under 20% of around 60,000 patients affected by diffuse Large B Cell Lymphoma (DLBCL) are potential candidates for Azer-cel, point out the analysts.

FORECAST
Bell Potter forecasts a full year FY23 dividend of 0.00 cents and EPS of minus -0.80 cents.
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.60 cents.
Access Stockbroker Research History >

IMU STOCK CHART

FNArena News on IMU

1
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
2
The Short Report – 07 Dec 2023

Dec 07 2023 - Weekly Reports
3
The Short Report – 16 Nov 2023

Nov 16 2023 - Weekly Reports
4
Next Week At A Glance – 25-29 Sep 2023

Sep 22 2023 - Weekly Reports
5
The Short Report – 07 Sep 2023

Sep 07 2023 - Weekly Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
2
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
3
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
4
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
5
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps
6
Dr Boreham’s Crucible: Imugene

Dec 11 2023 - Small Caps
7
Dr Boreham’s Crucible: PYC Therapeutics

Nov 22 2023 - Small Caps
8
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps
9
Dr Boreham’s Crucible: Argenica Therapeutics

Sep 28 2023 - Small Caps
10
Dr Boreham’s Crucible: Cleo Diagnostics

Aug 30 2023 - Small Caps